SLV308 for Treatment of Patients With Early Parkinson's Disease
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double blind, parallel group study of 6 months'
treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open
label safety extension to this study is planned as a separate protocol for patients who are
willing and eligible to participate.